Diagnostic Performance of Endocytoscopy for Colorectal Lesions
1 other identifier
observational
800
1 country
1
Brief Summary
Colorectal cancer is the third most common malignancy worldwide and the second leading cause of cancer-related death. About 70% of colorectal cancers develop through the adenoma-cancer pathway. Early detection and resection of colorectal neoplastic lesions significantly reduce the morbidity and mortality of colorectal cancers. Colonoscopy is considered to be the preferred method for screening for colorectal lesions. However, as the number of endoscopic resection increases, the costs associated with pathological diagnosis of endoscopic resection and resection specimens increase year by year. In clinical practice, it will be very important and urgent to correctly judge the nature of colorectal lesions to avoid pathological diagnosis and then realize optical biopsy. Therefore, to clarify the endoscopic diagnosis of colorectal lesions, many endoscopic techniques have been applied clinically. Such as narrow-band imaging, magnifying narrow-band imaging endoscopy, magnifying chromoendoscopy and endocytoscopy. Endocytoscopy has two modes, EC-NBI mode and EC-staining mode. EC-NBI mode is to observe the microvessel on the mucosal surface of colorectal mucosa after switching the endoscopy to NBI mode. EC-V pattern is used to observe microvessels and then endoscopic diagnosis is performed. The EC-staining mode was that the cell nuclei and glandular duct morphology of colorectal lesions could be observed by endocytoscopy after chemical staining. Endocytoscopic diagnosis is performed clinically after observation of glandular ducts and nuclei. However, current studies on the diagnostic value of endoscopy in colorectal lesions are all retrospective studies with small samples, and there is a lack of clinical studies based on chinese population. Therefore, our center intends to conduct a study of a large sample to explore the diagnostic value of endoscopy in colorectal lesions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 29, 2024
CompletedStudy Start
First participant enrolled
May 1, 2024
CompletedFirst Posted
Study publicly available on registry
May 3, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2025
CompletedMay 6, 2024
May 1, 2024
1 year
April 29, 2024
May 2, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (5)
sensitivity of diagnosing colorectal lesions using endocytoscopy
The percentage of patients with a specific type of colorectal disease who received a positive result by endocytoscopy.
May 2025
specificity of diagnosing colorectal lesions using endocytoscopy
The percentage of patients with non-specific types of colorectal disease who received a negative result using endocytoscopy.
May 2025
accuracy of diagnosing colorectal lesions using endocytoscopy
The percentage of correct results that is obtained by endocytoscopy.
May 2025
positive predictive value of diagnosing colorectal lesions using endocytoscopy
The percentage of patients with positive results when using endocytoscopy to diagnose colorectal lesions.
May 2025
negative predictive value of diagnosing colorectal lesions using endocytoscopy
The percentage of non-patients with negative results when using endocytoscopy to diagnose colorectal lesions.
May 2025
Eligibility Criteria
The investigators analyzed only endoscopically or surgically resected colorectal lesions that had been observed and diagnosed with endoscopic methods by endoscopists that were ultimately performed histopathologic examination.
You may qualify if:
- colorectal lesions
You may not qualify if:
- non-epithelial tumors
- a history of inflammatory bowel disease
- lesions without clear EC images
- specific pathological types
- familial adenomatous polyposis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mingqing Liu
Changchun, Jilin, 130021, China
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Head of Gastroenterology and Endoscopy Center, Principal Investigator, Clinical Professor
Study Record Dates
First Submitted
April 29, 2024
First Posted
May 3, 2024
Study Start
May 1, 2024
Primary Completion
May 1, 2025
Study Completion
May 1, 2025
Last Updated
May 6, 2024
Record last verified: 2024-05